This page shows what was measured, who it was measured in, and what that does not settle.
What Ascorbic acid does in the body
RNAWiki has not recorded what this substance changes in the body.
From the FDA-approved label: The primary mode of action is osmotic action of the components of PLENVU (PEG 3350 plus sodium sulfate components in Dose 1, and sodium ascorbate and ascorbic acid plus PEG 3350 components in Dose 2) which induce the laxative effect. The physiological consequence is increased water retention in the lumen of the colon, resulting in loose stools.
What happened in people
RNAWiki has not yet published a reviewed conclusion for this use.
§ A fixed RNAWiki sentence
Where this came from
Wording RNAWiki always uses, not a finding about this substance.
No reviewed claim names a result for any goal on this record.
No source is stored against this line.
The limit that matters most
Not recorded.
Where it acts
Not recorded.
Kind of result
No result is published, so no kind of result applies yet
Supervision
Not usually supervised: sold as a supplement or food ingredient where recorded. That is a legal category, not a safety judgement.
What the registries record it as
The substance registry classes this as chemical.
FDA substance registry · PQ6CK8PD0R · read 2026-08-29
The supplement label database classes it as mineral, under the name Calcium.
No recorded sentence describes the change this makes in a way that stands on its own.
No recorded use is stored in reader language.
No statement of the main limit is recorded.
The four opening statements run to 85 words.
Words this page uses
Four words worth knowing first
Chosen from what this page shows, with each one explained before the word it depends on.
Stand-in result
A stand-in result is a number measured because the real result takes too long.
A picture of it, and where the picture fails
It is like judging a journey by the speedometer rather than by arriving.
Where that stops being true. Speed does predict arrival. Many stand-in results do not predict the real one.
What people get wrong. A stand-in result is often reported as the result itself.
A surrogate endpoint substituted for a clinical endpoint, valid only where the substitution has been shown to hold.
Formulation
A formulation is the exact made-up form a substance comes in.
A picture of it, and where the picture fails
It is like the difference between a whole bean and instant coffee.
Where that stops being true. Coffee tastes different. A formulation can change how much reaches the blood.
What people get wrong. Two products with the same name are assumed to behave the same. They often do not.
The specific composition and physical form of a product, including salt, excipients and release profile.
Receptor
A receptor is a part of a cell that a signal fits into.
A picture of it, and where the picture fails
A receptor is like a lock waiting for one key.
Where that stops being true. A lock either opens or does not. A receptor can be half-triggered, or worn out.
What people get wrong. Fitting a receptor is read as causing a benefit. It causes a step, and nothing more.
A protein that binds a specific ligand and converts that binding into a cellular response.
Pathway
A pathway is a chain of steps inside a cell, each one setting off the next.
A picture of it, and where the picture fails
A pathway is like a row of dominoes.
Where that stops being true. Dominoes fall one way. Pathways loop back and can switch themselves off.
What people get wrong. Changing one step is read as changing the outcome. Other steps often absorb it.
An ordered series of molecular interactions producing a defined cellular change.
What happened in people◇Read from sources, not yet reviewed
What was measured, goal by goal
One row for each goal a registered study measured something for. One column for each kind of thing that could be measured.
Registered studies list 40 outcome measures that RNAWiki could read. A registered study says what someone planned to measure. It does not say what they found. 0 of the matched studies tested this substance, and 0 posted a result.
There is no single score. A strong test result and a weak life result are different facts.
Goals down the side, kinds of measurement across the top. Each cell says what kind of thing was registered, not what was found.
Goal
Life outcome
What a body can do
How a person feels
A test result
A step in the body
Harms
How long
Who was studied
Healthy ageing
…Waiting for a reviewer1 registered study measure of this kind. No reviewed result yet.
∅Nothing in the sources checkedNo registered study lists a performance measure for this goal.
∅Nothing in the sources checkedNo registered study lists a symptom measure for this goal.
△Only a number moved1 registered test measure.
∅Nothing in the sources checkedNo registered study lists a body-step measure for this goal.
—Not recordedHarms were not a registered measure for this goal.
—Not recordedNo finished study window is recorded.
…Waiting for a reviewerWho was studied is listed further down the page.
Which registered measures put each goal on this table
Healthy ageing
mortality; antioxidant and dna methylation
Sorted by fixed word lists, version v1. A name the rules do not recognise stays unsorted rather than moving to the nearest column.
What each mark on this table means
… Waiting for a reviewer
1 registered study measure of this kind. No reviewed result yet.
∅ Nothing in the sources checked
No registered study lists a performance measure for this goal.
△ Only a number moved
1 registered test measure.
— Not recorded
Harms were not a registered measure for this goal.
What happened in people◇Read from sources, not yet reviewed
What happened in people
Each card is one study: the exact question it asked, who was in it, and whether it showed what it set out to show.
lung injury score
✗ The study did not show it
Who was studied
NCT04353180
How many people
100000
Study design
Phase 3
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Oral
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA Drugs@FDA · a recorded source, not a stored snapshot
openFDA NDC Directory · a recorded source, not a stored snapshot
openFDA SPL label · a recorded source, not a stored snapshot
NIH Dietary Supplement Label Database · a recorded source, not a stored snapshot
Infant Mortality Through 6 mo of Age
✗ The study did not show it
Who was studied
NCT00860470
How many people
44567
Study design
Phase 3
Compared against
Not recorded for this study
Kind of result
Living longer, or avoiding a major event
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Oral
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA Drugs@FDA · a recorded source, not a stored snapshot
openFDA NDC Directory · a recorded source, not a stored snapshot
openFDA SPL label · a recorded source, not a stored snapshot
NIH Dietary Supplement Label Database · a recorded source, not a stored snapshot
Anemia status
✗ The study did not show it
Who was studied
NCT03287882
How many people
25447
Study design
Phase 3
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Oral
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA Drugs@FDA · a recorded source, not a stored snapshot
openFDA NDC Directory · a recorded source, not a stored snapshot
openFDA SPL label · a recorded source, not a stored snapshot
NIH Dietary Supplement Label Database · a recorded source, not a stored snapshot
All-cause mortality
✗ The study did not show it
Who was studied
NCT02735707
How many people
20000
Study design
Phase 3
Compared against
Not recorded for this study
Kind of result
Living longer, or avoiding a major event
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Oral
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA Drugs@FDA · a recorded source, not a stored snapshot
openFDA NDC Directory · a recorded source, not a stored snapshot
openFDA SPL label · a recorded source, not a stored snapshot
NIH Dietary Supplement Label Database · a recorded source, not a stored snapshot
Prostate cancer
✗ The study did not show it
Who was studied
NCT00270647
How many people
14641
Study design
Not applicable
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Oral
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA Drugs@FDA · a recorded source, not a stored snapshot
openFDA NDC Directory · a recorded source, not a stored snapshot
openFDA SPL label · a recorded source, not a stored snapshot
NIH Dietary Supplement Label Database · a recorded source, not a stored snapshot
Prevalence, incidence, and incidence of renal disease progression in children with CKD
✗ The study did not show it
Who was studied
NCT06018831
How many people
13000
Study design
Not applicable
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Oral
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA Drugs@FDA · a recorded source, not a stored snapshot
openFDA NDC Directory · a recorded source, not a stored snapshot
openFDA SPL label · a recorded source, not a stored snapshot
NIH Dietary Supplement Label Database · a recorded source, not a stored snapshot
What we know
RNAWiki holds 6 written-up human studies for this substance, each with the question it asked.
How we know it
Each card names the study, the number of people and what the study set out to measure.
What this does not prove
These summaries were written by a person and have not been signed off as reviewed claims.
Why it matters
A study that failed is as informative as one that worked, and both are here.
What we still do not know
No reviewed claim exists, so no exact population, effect size or interval is published yet.
What happened in people◇Read from sources, not yet reviewed
How close this is to real life
The top step is something a person would feel or care about. The bottom is a guess from software. Filled steps are where evidence exists for this substance.
■Living longer, or avoiding a major eventEvidence recorded. Death, a heart attack, a stroke, a hospital stay.1 registered measure of this kind. 1 written-up study measured this and did not show a benefit.
□What a body can do day to dayNo evidence recorded. Walking, dressing, breathing, recovering.No registered study measures this.
□Measured performanceNo evidence recorded. How much was lifted, how far was run, how fast.No registered study measures this.
□Symptoms and quality of lifeNo evidence recorded. Pain, tiredness, mood, sleep, as the person rated it.No registered study measures this.
■A number that stands in for healthEvidence recorded. Cholesterol, blood sugar, bone density. A stand-in, not the thing itself.7 registered measures of this kind.
■A step measured inside a personEvidence recorded. Something measured in human tissue or human cells.A human record sits on the stored organism ladder.
■AnimalsEvidence recorded. Mice, rats, dogs. Useful for ideas, not proof about people.Stored records in Yeast, Drosophila (fruit fly), Mouse. A result in animals says what to test next. It does not say what happens in people.
■Cells in a dishEvidence recorded. Cells or chemistry on a bench, far from a whole body.Stored mechanism abstracts describe steps measured in cells or tissue.
□A guess from softwareNo evidence recorded. Nobody measured it. RNAWiki never publishes one as a finding.RNAWiki stores no prediction for this record. Software can suggest a link. RNAWiki does not publish one as a finding.
Higher on these steps means closer to something a person would feel. It does not mean better done.
What it would be like to take◇Read from sources, not yet reviewed
Felt, measured, or meaningful
Three different things that get called the same word. Registered studies measured all three, and mixing them is how a blood test becomes a health claim.
Felt
Things a person could notice without a test.
No registered study measured anything of this kind.
Measured
Things only a test, a scale or a device shows.
high sensitivity c reactive protein
blood pressure
time to reach plasma paracetamol concentration of 0 25
antioxidant and dna methylation
heart rate
systolic blood pressure
diastolic blood pressure
Meaningful
Things that change how a life goes, not only a number.
mortality
A registered study says what someone planned to measure. It does not say what they found. A number moving is not the same as a life going better. The two are shown apart here.
Felt, but not shown to help. A person notices a change. No study showed it leads anywhere good.
Measured, but not felt. A number moves. The person notices nothing. Both can be true.
Measured, but not shown to matter. A number moves in the good direction. Nobody showed that lives went better.
Matters, but takes years. The result that counts may take longer than anyone would keep watching.
Names that fit none of the three (32)
cardiovascular disease
cancer
brief psychiatric rating scale
global clinical assessment
adverse events by nci ctc version 3 0
prostate cancer
total cancer
major cardiovascular events
response rate at 6 months
overall response rate
responding
behavioral test scores
ddst ii
neurological examination
response rate
connors 3 parent rating scale
extension of florscein paint on the cornea and conjunctiva
lvef
peak oxygen consumption
skin aging measured the photonumeric scale
These are harms, study-process measures, or names the rules did not recognise. They are shown rather than dropped.
What is missing or unclear◇Read from sources, not yet reviewed
Were people like you studied?
RNAWiki cannot tell whether a study fits you. It can show who was in it, and where the result stops carrying.
Who was studied
People similar to this profile were included.
Supplementation of the diet with fluoride and ten essential vitamins. Multivitamin with 1.0 mg Fluoride Chewable Tablets provide fluoride in tablet form for children 6-16 years of age in areas where the water fluoride level is less than 0.3 ppm.
Who is missing from the studies
Which groups were under-represented in the studies has not been recorded for this substance. Pregnancy, breastfeeding, children, older adults, and people with liver or kidney conditions are commonly excluded from trials; nothing here says whether they were.
Where the result stopped carrying
This is a scope explorer, not a diagnosis engine.
It shows who was studied so you can see whether people similar to you were included.
RNAWiki cannot tell whether a study fits you. It can show who was in it.
What it would be like to take◇Read from sources, not yet reviewed
Why it might seem to do nothing
A real effect and a noticed effect are different things. These are the recorded reasons the two come apart.
It was studied for a different goal
The studies measured something else entirely.
On this record: Some registered studies measured things that match no goal on this page.
It was studied in different people
The people in the studies were not much like the reader.
On this record: Which groups were under-represented in the studies has not been recorded for this substance. Pregnancy, breastfeeding, children, older adults, and people with liver or kidney conditions are commonly excluded from trials; nothing here says whether they were.
A different form was studied
The studied form is not the form on the shelf.
On this record: This record is linked to 1 related forms. Evidence does not carry across all of them.
The evidence may simply be wrong
Small early studies often do not hold up.
On this record: RNAWiki has not yet published a reviewed conclusion for this use.
Other reasons RNAWiki checked and found nothing for (9)
There was nothing to correct
Where a level is already normal, topping it up may change nothing. Nothing in this record points to this reason.
Something else had to happen too
In the studies it was paired with training, a diet or another treatment. Nothing in this record points to this reason.
The change is too small to feel
A real change can still sit below what a person notices. Nothing in this record points to this reason.
Day-to-day swing hides it
Sleep, food, stress and time of day move most numbers more than this would. Nothing in this record points to this reason.
Not enough time yet
The studies ran longer than the person has waited. Nothing in this record points to this reason.
It was not taken as studied
Missed days change the result, and studies count them. Nothing in this record points to this reason.
Something else changed at the same time
Two changes at once cannot be told apart afterwards. Nothing in this record points to this reason.
The product may not be what it says
Contents of a sold product are not always what the label states. Nothing in this record points to this reason.
No recorded reason
RNAWiki has nothing stored that would explain it. Nothing in this record points to this reason.
None of these is a reason to take more. Taking more is not a step this page ever suggests.
What it would be like to take◇Read from sources, not yet reviewed
What taking it involves
The recorded facts about getting hold of it and using it. Nothing here is a suggestion about what you should do.
How it is supplied
Prescription only
❝ Quoted from a source
Where this came from
Copied from a source RNAWiki stored, with the source named.
Read from the recorded approval status.
No source is stored against this line.
Form and route
Oral
✎ Source-linked record
Where this came from
A person wrote this into the record with the study named beside it. No reviewer has signed it off.
The form and route recorded on this substance.
No source is stored against this line.
Who oversees it
Not usually supervised: sold as a supplement or food ingredient where recorded. That is a legal category, not a safety judgement.
❝ Quoted from a source
Where this came from
Copied from a source RNAWiki stored, with the source named.
The identity record classes it as a supplement ingredient; no medicines register records an approval.
No source is stored against this line.
What is in the pack
Sold as for solution, tablet, tablet, chewable, capsule, gelatin coated, given by the oral, cutaneous route.
✎ Source-linked record
Where this came from
A person wrote this into the record with the study named beside it. No reviewer has signed it off.
Recorded notes on how this is sold and what that means for what is in the pack.
No source is stored against this line.
Where it is registered
Regulatory records are listed in the technical disclosure at the foot of this page.
# Counted from records
Where this came from
A count of rows RNAWiki holds. It describes our records, not your body.
Register entries are stored per jurisdiction and shown with their dates.
No source is stored against this line.
Why people stop
Not recorded.
∅ Nothing recorded
Where this came from
RNAWiki holds nothing here and says so rather than guessing.
No record of why people stopped taking it is stored for this substance.
No source is stored against this line.
What it would be like to take∅Nothing found in the sources checked
What can go wrong
Sorted by where each line came from. A regulator's label and a report somebody sent in are not the same kind of fact.
∅Nothing found in the sources checked
No harm is recorded against this substance in the sources RNAWiki checked. Finding nothing is not the same as showing there is nothing.
The sources listed were searched and held nothing. That is not the same as nothing existing.
Reports sent to a regulator
These are reports people sent to a regulator. They do not show the medicine caused the reaction.
Nobody counted how many people took the medicine and reported nothing.
The same event can be reported more than once, and many reports are incomplete.
News coverage, lawsuits and new warnings change how often people report.
A count is not a rate and not a risk.
Ascorbic acid appears in spontaneous reports to regulators. Across the 10 most-reported reaction terms, 23131 reaction mentions were counted. One report can name several reactions.
open-targets-adr · recorded 2026-06-24 · a recorded source, not a stored snapshot
Over a long time. No completed tested study window is recorded, so long-term effects are not established by the registry record.
Groups the studies covered thinly. Which groups were under-represented in the studies has not been recorded for this substance. Pregnancy, breastfeeding, children, older adults, and people with liver or kidney conditions are commonly excluded from trials; nothing here says whether they were.
What is missing or unclear◇Read from sources, not yet reviewed
Does the exact form matter?
Evidence belongs to the exact thing that was tested. A different salt, a different mixture or a different preparation is a different question.
The form that was studied
Oral
✎ Source-linked record
Where this came from
A person wrote this into the record with the study named beside it. No reviewer has signed it off.
The form used in the studies cited on this page.
No source is stored against this line.
What is sold
Not recorded.
∅ Nothing recorded
Where this came from
RNAWiki holds nothing here and says so rather than guessing.
Nothing further is recorded about which forms are sold.
No source is stored against this line.
What is recorded as being sold
17 published labels name it as an active ingredient. None of them describes this substance alone, so no label text on this page can be attributed to it rather than to a combination.
US prescribing information · 30186998-2121-3ef2-e063-6394a90a513e · read 2026-08-29
Those labels are classed as human prescription drug.
US prescribing information · 30186998-2121-3ef2-e063-6394a90a513e · read 2026-08-29
Se-Natal 19 Chewable is oral at HOW SUPPLIED Se-Natal 19 Chewable Tablets for oral administration are supplied as multi-color-speckled, round tablets debossed "TL015," packaged in bottles of 100 tablets., recorded as fda label in effect 2025-03-12 in the United States.
US prescribing information · a54dd642-8884-415a-a082-cd9fb544e400 · read 2026-08-30
Evidence carries across two names for one substance. It does not carry across a salt, a mirror form or a mixture.
This order is fixed in code and does not count clicks or time on the page.
What is not here
6 questions this page could not answer
These sections were prepared and left out because there was nothing to put in them. They are listed rather than hidden, so the gaps in this record are visible.
The path through the body — found nothing in the sources checked.
How long anything takes — found nothing in the sources checked.
What it may clash with — found nothing in the sources checked.
Other ways to the same goal — found nothing in the sources checked.
Claims that go past the evidence — found nothing in the sources checked.
What changed on this page — found nothing in the sources checked.
The record as stored
The full record, for auditing
Everything above is built from what is below. This layer keeps the technical vocabulary, record identifiers and every stored row, so a reader who wants to check the page can.
Recorded evidence blocks (14)
Q1
What did Ascorbic acid's largest trial (20000 people) and its longest (22 years) measure?
20000 people in Ascorbic acid's largest registered study, 22 years in its longest registered window, measuring Skin Aging Measured With the Photonumeric Scale. ClinicalTrials.gov · 2026-09-01
120 phase2, 86 na, 57 phase1, 57 phase3, 49 phase4, 13 early phase1, 10 na or unstated; NCT00001309; 2019-03-04. Last human test completed 2025, NCT02390505.
Interpretation These counts include studies where Ascorbic acid was a comparison treatment, a background treatment or an exposure in an observational study, and the longest window may be a planned end date. Trial roles have not yet been classified for this record.
Show the evidence
phase2
120
na
86
phase1
57
phase3
57
phase4
49
early phase1
13
2 more recorded rows
na or unstated
10
Last recorded human testNCT02390505
2025-12-08
recorded 2026-09-01 · last checked 2026-09-04
Q2
From yeast to human: where has Ascorbic acid shown lifespan?
20 recorded entries; human; also "Redoxon, Vitamin C 1000mg, Bayer LSR912 MFD", "vitamin C 500 mg", "ascorbic acid 10g/20ml"
Show the evidence
human
NCT01125449
Bioniche ascorbic acid, parenteral, 500mg/ml
NCT01322061
Redoxon, Vitamin C 1000mg, Bayer LSR912 MFD
NCT01751087
vitamin C 500 mg
NCT01926132
ascorbic acid 10g/20ml
NCT02132091
1000 mg Vitamin C
NCT02422901
Pascorbin® 7.5g
14 more recorded rows
humanNCT02639741
Vitamin C 1000 mg tb
humanNCT03252418
Ascorbic Acid 500 MG
humanNCT03269799
Vitamin C 500 MG Oral Capsule
humanNCT03524846
Ascorbic Acid 300 MG
humanNCT03524846
Ascorbic Acid 600 MG
humanNCT03725384
Ferrous Sulfate 300Mg Tablet
humanNCT03800667
Ascorbic Acid 1000 MG
humanNCT03849443
Vitamin C 250 MG Oral Tablet
humanNCT04036110
Vitamin C 1000 mg
humanNCT04261036
Ascorbic Acid 1000 mg
humanNCT05414474
Ascorbic acid (AA) 500 mg
humanNCT05414474
Ascorbic acid (AA) 80 mg
humanNCT05810233
Ascorbic acid 1000mg
humanNCT06190483
Ascorbic Acid 50 Mg Oral Tablet
recorded 2026-09-01 · last checked 2026-09-04
Q5
More Ascorbic acid was worse in human: at what point?
U-shaped in human: "Dietary ascorbic acid intake and circadian hepcidin rhythms emerged as relevant determinants of iron absorption and systemic iron dynamics.ConclusionsBoth iron deficiency and iron excess are associated with adverse outcomes, reflecting a U-shaped relationship between iron status and risk." Europe PMC · dose-response search · 2026-06-23
3 recorded sentences naming Ascorbic acid; U-shaped, dose-response, biphasic
Show the evidence
U-shapedPMID 42309512
"Dietary ascorbic acid intake and circadian hepcidin rhythms emerged as relevant determinants of iron absorption and systemic iron dynamics.ConclusionsBoth iron deficiency and iron excess are associated with adverse outcomes, reflecting a U-shaped relationship between iron status and risk."
dose-responsePMID 42334245
"Compared with BO (2.24 ± 0.003 mg ascorbic acid equivalent [AAE] g⁻¹), OPG exhibited a significantly higher total antioxidant capacity (23.40 ± 0.004 mg AAE g⁻¹), greater antifungal activity against Candida spp. (minimum inhibitory concentration (MIC) and minimum fungicidal concentration (MFC) = 5 mg mL⁻¹), and an enhanced redox-modulating dose-response in C. elegans."
biphasicPMID 41009988
"In addition, a biphasic response in the ascorbic acid cycle was found, with initial increases in enzyme activities followed by a decline, suggesting a temporary enhancement of antioxidant defenses."
recorded 2026-06-23 · last checked 2026-09-04
Q6
Could one person measure Ascorbic acid's effect on cardiovascular disease?
Cardiovascular disease: measured in Ascorbic acid's trials.
Interpretation cardiovascular disease is the recorded endpoint.
Show the evidence
biomarkers
cardiovascular disease; 2026-09-01
cancer; 2026-09-01
high sensitivity c reactive protein; 2026-09-01
brief psychiatric rating scale; 2026-09-01
global clinical assessment; 2026-09-01
adverse events by nci ctc version 3 0; 2026-09-01
14 more recorded rows
biomarkers
prostate cancer; 2026-09-01
biomarkers
total cancer; 2026-09-01
biomarkers
major cardiovascular events; 2026-09-01
biomarkers
response rate at 6 months; 2026-09-01
biomarkers
overall response rate; 2026-09-01
biomarkers
responding; 2026-09-01
biomarkers
behavioral test scores; 2026-09-01
biomarkers
ddst ii; 2026-09-01
biomarkers
neurological examination; 2026-09-01
biomarkers
response rate; 2026-09-01
biomarkers
connors 3 parent rating scale; 2026-09-01
biomarkers
extension of florscein paint on the cornea and conjunctiva; 2026-09-01
biomarkers
lvef; 2026-09-01
biomarkers
blood pressure; 2026-09-01
human trials at or under30
122
Not recorded for this substance
a recorded half-life
smallest human trial
0; NCT00001070; NA; the smallest recorded human enrolment at or below 30; the registry states no direction of its result; WITHDRAWN
Q7
Which of adverse events as a measure of safety and tolerability, adverse events by nci ctc version 3 0 and antioxidant and dna methylation did Ascorbic acid's trials measure?
adverse events as a measure of safety and tolerability, adverse events by nci ctc version 3 0 and antioxidant and dna methylation lead 40 outcome terms across Ascorbic acid's trials. ClinicalTrials.gov · 2026-09-01
brief psychiatric rating scale, global clinical assessment, adverse events by nci ctc version 3 0, prostate cancer, total cancer and major cardiovascular events follow.
Show the evidence
cardiovascular disease
1
cancer
1
high sensitivity c reactive protein
1
brief psychiatric rating scale
1
global clinical assessment
1
adverse events by nci ctc version 3 0
1
14 more recorded rows
prostate cancer
1
total cancer
1
major cardiovascular events
1
response rate at 6 months
1
overall response rate
1
responding
1
behavioral test scores
1
ddst ii
1
neurological examination
1
response rate
1
connors 3 parent rating scale
1
extension of florscein paint on the cornea and conjunctiva
1
lvef
1
blood pressure
1
recorded 2026-09-01 · last checked 2026-09-04
Q8
Which of Ascorbic acid's 35 ongoing trials reports first?
"Nitric Oxide Bioavailability and Early Life Stress (NO-Stress)"; n 74; "Acute Change in Flow mediated dilation"; 2027-01
NCT02344355
"A Phase 2 Trial of High-Dose Ascorbate in Glioblastoma Multiforme"; n 90; "Overall Survival (OS)"; 2028-12
NCT02690064
"Mechanisms for Vascular Dysfunction and Exercise Tolerance in CF"; n 13; "Acute Change in Flow mediated dilation"; 2027-01
NCT02735707
"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia"; n 20000; "All-cause mortality"; 2028-02
NCT02905591
"A Phase 2 Study Adding Ascorbate to Chemotherapy and Radiation Therapy for NSCLC"; n 43; "Progression Rate at the Completion of Radiation and Chemotherapy"; 2027-12-31
NCT03408886
"Microbiota Transfer Therapy for Adults With Autism Spectrum Disorder (ASD) Who Have Gastrointestinal Disorders"; n 55; "Change in Childhood Autism Rating Scale (CARS) from baseline to 10 weeks"; 2024-12-15
14 further recorded trials
NCT03418038
"Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia"; n 80; "Overall response rate (ORR) (Arms A and B)"; 2033-11-02
NCT03849443
"Single Versus Multi-Dose Oral and Intravenous Tranexamic Acid Patients at High Risk for Blood Transfusion After Spine Surgery"; n 604; "Postoperative blood loss"; 2027-01-01
NCT03999723
"Combining Active and Passive DNA Hypomethylation"; n 196; "Event-free survival"; 2027-12
NCT04046094
"Intravenous (IV) Vitamin C With Chemotherapy for Cisplatin Ineligible Bladder Cancer Patients"; n 12; "Post Treatment Pathological Staging"; 2026-08
NCT04150042
"SHARON: A Clinical Trial for Metastatic Cancer Using Chemotherapy and Patients' Own Stem Cells"; n 24; "Rate of Sinusoidal obstruction syndrome"; 2028-12
NCT04268849
"Trial of IV vs Oral Iron Treatment of Iron Deficiency Anemia in the Post-Operative Bariatric Surgical Patient"; n 104; "Change in Clinical Global Impression - improvement scale (CGI-2) score at 6 weeks after treatment begins."; 2026-02
NCT04516681
"Combination of IV Ascorbic Acid and Adebrelimab in Metastatic Colorectal Cancer"; n 400; "Objective Response Rate"; 2025-12-01
NCT04634227
"Gemcitabine Plus Ascorbate for Sarcoma in Adults (Pilot)"; n 30; "Determine the 12 weeks progression free survival (PFS 12) at 12 weeks post treatment initiation"; 2026-12-31
NCT04715022
"Sympathetic-vascular Dysfunction in Obesity and Insulin Resistance (Vitamin C Study)"; n 23; "Efficacy of infusion of ascorbic acid"; 2027-08-01
NCT04800692
"The Effects of ATLAS Therapy on Nitric Oxide Bioavailability in Patients With Intermittent Claudication"; n 10; "Nitric Oxide bioavailability"; 2027-12
NCT04832009
"Reversing Glucose and Lipid-mediated Vascular Dysfunction"; n 46; "Efficacy of Infusion of Ascorbic Acid"; 2027-08-01
NCT04900792
"A Safety Study of Pharmacologic Ascorbate and Ferumoxytol in Addition to Standard of Care Chemoradiation in Glioblastoma"; n 16; "Number of Ferumoxytol-related Dose Limiting Toxicities (DLTs)"; 2026-12-31
NCT05436054
"A Trial to Compare Efficacy and Tolerability of Plenvu® and Picoprep® as Cleansing Agents Before Colonoscopy"; n 400; "Efficacy of cleansing agent"; 2025-12-01
NCT05849129
"Adjunctive Intravenous Ascorbic Acid for Advanced Non-Small Cell Lung Cancer"; n 90; "Change in Quality of Life"; 2031-10-01
recorded 2026-09-01 · last checked 2026-09-04
Q9
Which running trial of Ascorbic acid could settle lifespan?
NCT04634227 measures Determine the 12 weeks progression free survival (PFS 12) at 12 weeks post treatment initiation, reading out 2026-12-31.
4 open trials; n 30; "Gemcitabine Plus Ascorbate for Sarcoma in Adults (Pilot)"
Show the evidence
Trial
NCT04634227
"Gemcitabine Plus Ascorbate for Sarcoma in Adults (Pilot)"; n 30; "Determine the 12 weeks progression free survival (PFS 12) at 12 weeks post treatment initiation"; 2026-12-31
NCT03999723
"Combining Active and Passive DNA Hypomethylation"; n 196; "Event-free survival"; 2027-12
NCT02735707
"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia"; n 20000; "All-cause mortality"; 2028-02
NCT02344355
"A Phase 2 Trial of High-Dose Ascorbate in Glioblastoma Multiforme"; n 90; "Overall Survival (OS)"; 2028-12
Q10
Which 142 trials of Ascorbic acid posted no result?
Posted no result
142 of 142 completed trials
Registrations
NCT00000539, NCT06597903, NCT00389233, NCT00322062, NCT00000555 and NCT00427089, and 136 more
Completion dates
oldest 1999-03; newest 2024-09-01
Show the evidence
Trial
NCT00000539
1999-03
NCT06597903
2002-03
NCT00389233
2002-12
NCT00322062
2003-03
NCT00000555
2003-05
NCT00427089
2005-05
14 further recorded trials
NCT00000541
2005-07
NCT00356954
2006-04
NCT00624871
2006-04
NCT00312481
2006-05
NCT00896246
2006-11
NCT00284427
2006-12
NCT00006021
2007-03
NCT00534014
2007-05
NCT00271635
2007-07
NCT00228319
2007-08
NCT00274820
2007-10
NCT00142610
2007-12
NCT00605228
2007-12
NCT00079963
2008-03-24
Q11
At the median, Ascorbic acid's trials enrolled 53 people — anything larger?
Median enrolment
53
Largest enrolment
20000
Registered trials counted
346
Q12
What do 23131 spontaneous reports say about Ascorbic acid — and not say?
These are reports people sent to a regulator. They do not show the medicine caused the reaction. Nobody counted how many people took the medicine and reported nothing. The same event can be reported more than once, and many reports are incomplete. News coverage, lawsuits and new warnings change how often people report. A count is not a rate and not a risk.
Ascorbic acid appears in spontaneous reports to regulators. Across the 10 most-reported reaction terms, 23131 reaction mentions were counted: pain 2768; alopecia 2564; abdominal discomfort 2524; pemphigus 2523. open-targets-adr · CHEMBL196 · 2026-06-24
Show the evidence
pain
2768
alopecia
2564
abdominal discomfort
2524
pemphigus
2523
systemic lupus erythematosus
2523
fatigue
2316
4 more recorded rows
rheumatoid arthritis
2299
glossodynia
2063
swelling
1848
hand deformity
1703
recorded 2026-06-24 · last checked 2026-09-04
Q13
Was Ascorbic acid studied with exercise?
exercise is named in Ascorbic acid's label sentences: "In subgroups of women, FMD also was measured during the infusion of ascorbic acid at baseline and following estradiol/placebo plus endurance exercise training, and in seven habitually endurance-trained estrogen-deficient controls." openfda-label+europepmc · 2013-10-03
1 recorded statement; exercise
Show the evidence
exercise
In subgroups of women, FMD also was measured during the infusion of ascorbic acid at baseline and following estradiol/placebo plus endurance exercise training, and in seven habitually endurance-trained estrogen-deficient controls.
recorded 2013-10-03 · last checked 2026-09-04
Q14
What is recorded about Ascorbic acid and mTOR?
"Knock down SLC23A2 in human embryonic palatal mesenchymal cell line (HEPM) induced decreased intracellular ascorbic acid (AA), increased reactive oxygen species (ROS), inhibited cell proliferation and triggered apoptosis, activated the PI3K-AKT-mTOR signaling pathway and inhibited autophagy; ROS levels and apoptosis ratio significantly…" — where Ascorbic acid and mTOR appear together. Europe PMC · pathway abstract search · 2025-06-02
"Knock down SLC23A2 in human embryonic palatal mesenchymal cell line (HEPM) induced decreased intracellular ascorbic acid (AA), increased reactive oxygen species (ROS), inhibited cell proliferation and triggered apoptosis, activated the PI3K-AKT-mTOR signaling pathway and inhibited autophagy; ROS levels and apoptosis ratio significantly decreased when we supplemented AA to HEPM cells with high ROS…"
autophagyPMID 40456835
"Knock down SLC23A2 in human embryonic palatal mesenchymal cell line (HEPM) induced decreased intracellular ascorbic acid (AA), increased reactive oxygen species (ROS), inhibited cell proliferation and triggered apoptosis, activated the PI3K-AKT-mTOR signaling pathway and inhibited autophagy; ROS levels and apoptosis ratio significantly decreased when we supplemented AA to HEPM cells with high ROS…"
mTOR
PMID 36478125
"In addition, our data demonstrated that ascorbic acid inhibits p-AKT signaling in a ROS-dependent pathway, leading to inhibition of p-mTOR expression."
PMID 36478125
"And metformin inhibits the p-mTOR expression by activating the AMPK signaling pathway, exerting a synergistic effect on tumor suppression with ascorbic acid."
AMPK
PMID 36478125
"And metformin inhibits the p-mTOR expression by activating the AMPK signaling pathway, exerting a synergistic effect on tumor suppression with ascorbic acid."
PMID 36478125
"Ascorbic acid inhibits the mTOR expression via PI3K-AKT pathway, and metformin inhibits the mTOR expression by inhibiting AMPK signaling in prostate cancer cells."
autophagyPMID 37036607
"HMGB1 was confirmed as a specific target of l-ascorbic acid, and si-HMGB1 treatment strengthened the beneficial effect of l-ascorbic acid on H/R-induced damage of CMECs, followed by further reduction in the proliferation and migration abilities of CMECs, as well as the increase in the inflammation and autophagy of CMECs."
recorded 2025-06-02 · last checked 2026-09-04
Where it is registeredIdentifiers, relations and other names
ChEMBL ATC CC BY-SA · ClinicalTrials.gov — US Government work · Europe PMC — metadata only, under the recorded legal gate · Open Targets 26.06 — CC0 · derived from this page's own recorded fields; no external licence · mixed register set; per-register licences in docs/specs/corpus-20k-sources.md · openFDA / DailyMed — US Government work
✗ required summary fields resolved: 5 required field(s) not terminal: Why people use it, Best-supported result, Most important common problem, Biggest unanswered question, Human evidence
✓ public claims reviewed: 0 reviewed claim(s); drafts are never rendered
✓ source coverage passed: 10 source rows
✓ no critical contamination: no quarantine open
✓ canonical metadata passed: slug and display name present
✓ no raw internal fields: enforced by the copy-contract test over the rendered page
This is a record of evidence. It is not medical advice, and it does not say this substance suits you. Nothing here says any substance on RNAWiki is appropriate for a child.